Welcome to our dedicated page for Barinthus Biotherapeutics plc SEC filings (Ticker: BRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Barinthus Biotherapeutics plc filings document material events, security structure, governance matters and clinical disclosures for a clinical-stage biopharmaceutical issuer organized in England and Wales. Recent Form 8-K reports describe American Depositary Shares listed under BRNS, with each ADS representing one ordinary share, along with capital-structure disclosures and emerging growth company status.
The company’s regulatory record also covers shareholder voting matters, material agreements, operating and financial results, clinical or regulatory updates related to its immunotherapy programs, and Nasdaq listing-compliance notices. These filings provide formal disclosure around the company’s ADR program, ordinary-share structure, board and governance matters, and public-company reporting obligations.